THERAPY DOSSIER · th-2e51bb7ba9ba

Potassium aspartate

Drug · Potassium aspartate (electrolyte salt); no curated ChEMBL mechanism record

Evidence & regulatory context

Mechanism: Potassium aspartate (electrolyte salt); no curated ChEMBL mechanism record
Target: Not recorded
Injury models: TBI
Reported indication: Not recorded
First approval: Not recorded
Development stage: Preclinical/no trial
ChEMBL record: CHEMBL3989852 ↗
ChEMBL max phase: -1 / 4 (development scale, not regulatory approval)
Synonyms: Potassium aspartate; L-aspartate potassium
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 27959885 ↗2016Reported benefit

Potassium Aspartate Attenuates Brain Injury Induced by Controlled Cortical Impact in Rats Through Increasing Adenosine Triphosphate (ATP) Levels, Na+/K+-ATPase Activity and Reducing Brain Edema.

RatTBIControlled cortical impactSprague-Dawley, specific pathogen freeMaleIntraperitoneal, volume 1 mL/kg10, 25, 62.5 and 125 mg/kg30 minutes after controlled cortical impact

Model: Controlled cortical impact under chloral hydrate anaesthesia with craniotomy of about 2.5 mm radius, PinPoint PCI3000 impactor at 1.5 m/s, depth 2.0 mm, dwell 85 ms

Potassium aspartate at 62.5 and 125 mg/kg improved neurological deficits and reduced cortical lesion volume, and 125 mg/kg attenuated brain oedema and blood-brain barrier disruption while raising ATP and Na+/K+-ATPase activity and lowering lactate.

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.85. Machine-extracted fields require source verification.

Loading the evidence…